62 results about "GLUT4" patented technology

The present invention is a method for identifying agents that modulate the GTPase activity of AS160. In the instant assay, AS160 or the GAP domain thereof is contacted with a test agent, in the presence of GTP-bound Rab (2A, 8A, 8B, 10, or 14), and the AS160 GAP domain-mediated hydrolysis of GTP to GDP is monitored.

The invention encompasses compositions and methods for effectively treating and / or preventing diabetes and / or obesity. This is accomplished by totally addressing the multiple mechanisms that lead to such conditions. The invention includes compositions comprising a combination of agents that effectively suppress, regulate or interfere with the various biochemical processes and mechanisms that lead to diabetes and obesity. The inventive compositions used for administration to human and other mammalian subjects comprise (1) at least one agent capable of modulating expression and / or activity of one or more of peroxisome activated protein receptor gamma (PPAR-γ), CAAT / enhancer binding protein-α (C / EBPα) and Sterol Regulatory Element-Binding Protein (SREBP-1); (2) at least one agent capable of activating Wnt / β-catenin pathway; (3) at least one agent capable of activating the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway; (4) at least one agent that inhibits the activity of pro-oxidants including reactive nitrogen species and reactive oxygen species (ROS); (5) at least one agent that suppresses one or more of inflammatory mediators including interleukins IL-1α, IL-1β, IL-6, NF-κB, TNF-α, matrix metalloproteinases (MMPs) and prostaglandin E2 (PGE2); (6) at least one agent capable of enhancing glucose transporter (GLUT4) and / or inhibiting glucose transporter GLUT2; (7) at least one agent that induces the expression of and / or activates adiponectin and (8) at least one agent that induces the expression of and / or activates sirtuin (SIRT1). The active agents for use herein are natural materials such as phytonutrients, vitamins and minerals. Compositions with combinations of such natural agents have the ability to prevent, reduce or treat diabetes and obesity by (a) clearing glucose and fatty acids from blood, (b) reducing the number of adipose cells and fat storage, (c) interfering with fat, glucose, and cholesterol biosynthesis, and (d) promoting fat and glucose oxidation.Since the present compositions are aimed toward normalizing metabolism and energy expenditure and managing oxidative stress and inflammation, they are also beneficial in relation to physical activity, in particular performance, endurance, fatigue and recovery during intensive and continuous exercise / exertion.

The present invention disclosed a medical use of cucurbitane triterpenoids represented by the following formula and isolated from Momordica charantia L. of Cucurbitaceae family in the preparation of medications for prevention and treatment of diabetes and obesity. The above cucurbitane triterpenoids may be acted as a glucose uptake stimulator, an agonist for the translocation of glucose transporter 4(GLUT4) to the cell membrane, and an activator of adenosine monophosphate-activated protein kinase (AMPK). They may have potential for the prevention and treatment of diabetes and obesity.

The invention belongs to the technical field of bioengineering and particularly relates to application of ginsenoside Rg1 in preparation of a health product capable of improving kinetism of organisms. Skeletal muscle contraction is a foundation for the organisms to achieve a kinetism function; the skeletal muscle contraction capacity is influenced by multiple factors, and the energy substance (glucose) extraction efficiency is one of key factors. Glucose uptake is finished mainly by virtue of a glucose transporter 4 on a skeletal muscle cell membrane, so that the gene expression and membrane translocation of skeletal muscle cell GLUT4 are increased, and glucose is a substance basis for skeletal muscle energy intake. Proven by experiments such as RT-PCR and Western blot, the ginsenoside R1g1 is capable of promoting the genetic transcription, protein expression, and membrane translocation of GLUT4skeletal muscle cell GLUT4, so that a health product capable of improving kinetism of organisms can be developed by use of the ginsenoside Rg1.

The invention relates to yeast strains in which a human GLUT4 transporter or a human GLUT1 transporter can be functionally expressed and in particular GLUT4 transport proteins which can be particularly easily functionally expressed in yeast strains.

The present invention relates to the identification of ALMS1 as the missing player involved in the regulation of the insulin-mediated glucose uptake through GLUT4 sorting vesicles, and to the down-regulation of ALMS1 by αPKC. Accordingly, the present invention relates to a molecule capable of preventing the binding of αPKC on ALMS1 for use for treating or preventing diabetes, in particular type 2 diabetes. In addition, the present invention relates to a method for identifying molecule capable of preventing the binding of αPKC on ALMS1.

The invention discloses an application of kappa-opioid receptor agonists U50 and 488H in preparation of drugs for treating diabetes. In the invention, the good blood sugar reducing effect of kappa-opioid receptor agonists U50 and 488H is creatively discovered, and the research shows that the blood sugar reducing mechanisms of kappa-opioid receptor agonist U50 and 488H are as follows: (1) increasing the level of skeletal muscle adiponectin receptor 1 (AdipoR1) and enhancing the sensitivity of adiponectin and insulin; (2) promoting the membrane translocation of glucose transporter (GLUT4) in skeletal muscle cell and increasing the glucose transport capability of the skeletal muscle cell; and (3) promoting the activation of AMPK (adenosine-monophosphate-activated protein kinase) in the skeletal muscle cell and enhancing insulin sensitivity. In the invention, a new option is provided for the preparation of the drugs for treating diabetes.

Disclosed herein is the use of a composition, containing isoflavone- containing soybean extract, L-carnitine, caffeine and arginine as active ingredients, for the treatment of obesity and diabetes. The disclosed composition contains isoflavone -containing soybean extract, carnitine, caffeine and arginine in the form of a mixture, and thus shows not only the effect of promoting lipolysis and fat burning, but also anti-obesity and anti-diabetic effects by increasing the expressions of adiponectin and Glut4 genes to restore insulin sensitivity.

The invention provides an application of an acridinedione compound in preparation of an anti-diabetic medicine, and belongs to the technical field of biological medicines. According to the invention,the results prove that the acridinedione compound can participate in a GPR40-PPAR gamma-PI3K / Akt-GLUT4 signal path by activating and up-regulating GPR40 protein expression so as to promote insulin secretion, increase glucose consumption of liver and muscle tissues and improve insulin resistance; the action target of the acridinedione compound is a GPR40 receptor, the insulin secretion promoting effect of the acridinedione compound has glucose dependence, and when the peripheral blood glucose is lower than a certain degree, the blood glucose reducing effect of the acridinedione compound disappears; and the acridinedione compound is prepared into the anti-diabetic medicine, and brand-new selection and strategy are provided for treatment of diabetes mellitus.

The invention relates to a probe and method for detecting the glucose transporter protein (GLUT4) membrane, to realize high pass screening. The red fluorescence protein TDimer2 for probe and pH-sensitive fluorescence protein pHluorin mark the insulin-sensitive IRAP protein (TDimer2-IRAP-pHluorin) to establish fat cell system and skeletal muscle cell system for stably expressing the TDimer2-IRAP-pHluorin protein and the effect of the insulin on the target cell can be adjudged by simply measuring the fluorescence ratio. Thus, the high pass screening of the medicine for activating the GLUT4 membrane can be performed by detecting the ratio variance of the pHluorin and TDimer2 fluorescence intensity after medicine activating. The method is simple and easy for high pass screening and industrialization with high sensitivity.

The present invention disclosed a medical use of cucurbitane triterpenoids represented by the following formula and isolated from Momordica charantia L. of Cucurbitaceae family in the preparation of medications for prevention and treatment of diabetes and obesity. The above cucurbitane triterpenoids may be acted as a glucose uptake stimulator, an agonist for the translocation of glucose transporter 4 (GLUT4) to the cell membrane, and an activator of adenosine monophosphate-activated protein kinase (AMPK). They may have potential for the prevention and treatment of diabetes and obesity.

The subject invention provides materials and methods for modulating cellular glucose uptake. Specifically, in accordance with one embodiment of the subject invention, stem cell factor (SCF) can be used to stimulate cellular glucose uptake. The administration of SCF can also be used to promote Glucose Transporter 4 (GLUT4) expression. In accordance with the subject invention, SCF can be used to improve glucose homeostasis, including in the treatment of diabetes mellitus.

The invention relates to 2'-O-rhamnosyl swertisin, preparation of analogues thereof, and application thereof. The 2'-O-rhamnosyl swertisin and the analogues thereof can obviously enhance the transposition of a glucose transporter GLUT4, accelerate absorption and utilization of glucose, obviously inhibit the rise of blood sugar, can be singly applied or are mixed with pharmaceutically acceptable medicinal auxiliary materials to form medicinal compositions or preparations, serve as medicaments for resisting type II diabetes and complications thereof, and are applied via gastrointestinal tracts or not. The preparation method comprises the steps of: separating from natural plant raw materials, chemically synthesizing and performing other means; and performing crushing, solvent extraction, weak-polarity macroporous adsorption resin separation, polyamide chromatographic column separation, sephadex gel chromatographic column separation, semi-preparative high performance liquid chromatograph purification and performing other processes.

Methods of treating cancer comprising administering inhibitors of glucose transporters (GLUTs) are provided. Methods of predicting whether a cancer will respond to treatment with a GLUT inhibitor also are provided.

The invention discloses an application of a common fenugreek seed extract and an extraction method thereof. The tests prove that a fenugreek ethanol extract can promote GLUT4 to transpose to a membrane by activating an AMPK signal path; finally, the glucose uptake capability of C2C12 cells is improved; therefore, the common fenugreek seed extract can be used for preparing products for improving the glucose uptake capacity of skeletal muscle cells, AMPK agonists and products with a hypoglycemic effect, can be further used for preparing products for treating and / or preventing obesity, insulin resistance and diabetes mellitus, contributes to research and development of a new generation of antidiabetic drugs taking AMPK as a new target, and brings good news to human health.

The present invention relates to the identification of ALMS1 as the missing player involved in the regulation of the insulin-mediated glucose uptake through GLUT4 sorting vesicles, and to the down-regulation of ALMS1 by αPKC. Accordingly, the present invention relates to a molecule capable of preventing the binding of αPKC on ALMS1 for use for treating or preventing diabetes, in particular type 2 diabetes. In addition, the present invention relates to a method for identifying molecule capable of preventing the binding of αPKC on ALMS1.

The invention discloses an andrographis paniculata ethyl acetate extract as well as a preparation method and an application thereof. Experimental research finds that the andrographis paniculata ethylacetate extract has relatively good activity of promoting GLUT4 to transport an upper membrane, and the activity can be inhibited by an AMPK inhibitor Compound C and a PKC inhibitor; and therefore, the andrographis paniculata ethyl acetate extract plays an active role through AMPK and PKC signal pathways. The andrographis paniculata ethyl acetate extract can up-regulate transcription and expression of GLUT4 protein. The invention provides a new research target for the basic research work of GLUT4, AMPK and PKC signal pathways, and is more helpful for carefully and deeply researching the physiological activity of cells.